Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi ...
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It ...
Get the latest news and real-time alerts from X4 Pharmaceuticals, Inc. (XFOR) stock at Seeking Alpha.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback